What is precision medicine? Precision medicine is, of course, a big step, but is probably not concerning all pediatric cancers. But we should not miss the opportunity to use it when it’s so active and so specific than, for instance, this Alectinib study. And the main barrier is the right and full documentation, molecular documentation of all pediatric cancers at diagnosis with sequencing, RNA sequencing, genome sequencing, and to have the data quickly available to make rapid changes in the treatment...
What is precision medicine? Precision medicine is, of course, a big step, but is probably not concerning all pediatric cancers. But we should not miss the opportunity to use it when it’s so active and so specific than, for instance, this Alectinib study. And the main barrier is the right and full documentation, molecular documentation of all pediatric cancers at diagnosis with sequencing, RNA sequencing, genome sequencing, and to have the data quickly available to make rapid changes in the treatment. So that is probably the main barrier and to have the results soon enough to be able to use these treatments, preferably in the context of clinical trials, except that we have already targeted treatments which are now standard treatment even in first line in some indications. But for those that are developed, we still need to do clinical trials. And this is a second barrier to have access to this drug through clinical trials in order to be able to be sure that they are about the efficacy and toxicity.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
